T-E. Ciuleanu

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)

Chandra P. Belani, T. Brodowicz, T-E. Ciuleanu et al. · Journal of Clinical Oncology · 2009 · 82 citations

Surgical Oncology, Advanced Lung Disease, Maintenance Pemetrexed +13

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

Hossein Borghaei, Kenneth J. O’Byrne, Luis Paz‐Ares et al. · ESMO Open · 2023 · 41 citations · Full text

Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status

Sanjay Popat, Andrea Ardizzoni, T-E. Ciuleanu et al. · Annals of Oncology · 2017 · 40 citations · Full text

European Single-arm, Preclinical Therapeutics, Urology +10

Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC).

Carsten Reinhardt, Romuald Zdrojowy, Cezary Szczylik et al. · Journal of Clinical Oncology · 2010 · 27 citations

Immunodeficiencies, Immunology, Immunoediting +24

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

Suresh S. Ramalingam, David Balli, T-E. Ciuleanu et al. · Annals of Oncology · 2021 · 25 citations

Advanced Nsclc, Part 1, Medicine +7